← Back to Clinical Trials
Recruiting NCT06230614

NCT06230614 Effect of Diluent Volume on Colistin Inhalation Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06230614
Status Recruiting
Phase
Sponsor Fu Jen Catholic University
Condition Inhalation Pneumonia
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-03-10
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type INTERVENTIONAL
Interventions
Colistin 1 MU in normal saline 1 mlColistin 1 MU in normal saline 2 ml

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-03-10 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to investigate the impact of different diluent volumes for the same dosage of colistin in mechanically ventilated respiratory patients receiving colistin inhalation therapy. The study aims to determine whether the diluent volume has an effect on clinical outcomes, including ICU length of stay, total hospitalization duration, duration of respiratory support within 28 days, mortality rates within 28 days and 90 days, as well as analyze the pharmacokinetic profile of colistin in blood and bronchoalveolar lavage fluid. Additionally, the study will evaluate the incidence of nebulizer malfunctions and blockages. The findings of this research will help identify the optimal diluent volume for colistin inhalation therapy in clinical practice.

Eligibility Criteria

Inclusion Criteria: * Admitted to the Intensive Care Unit. * Age greater than 18 years and using a ventilator due to acute respiratory failure. * Requires inhalation colistin treatment as determined by the disease. * Sign the written informed consent form. Exclusion Criteria: * Renal failure requiring renal dialysis. * Receiving both inhaled colistin and intravenous colistin treatments.

Contact & Investigator

Central Contact

Ke-Yun Chao, PhD

✉ C00152@mail.fjuh.fju.edu.tw

📞 +886-905-301-879

Principal Investigator

Ke-Yun Chao, PhD

PRINCIPAL INVESTIGATOR

Fu Jen Catholic University Hospital

Frequently Asked Questions

Who can join the NCT06230614 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Inhalation Pneumonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06230614 currently recruiting?

Yes, NCT06230614 is actively recruiting participants. Contact the research team at C00152@mail.fjuh.fju.edu.tw for enrollment information.

Where is the NCT06230614 trial being conducted?

This trial is being conducted at New Taipei City, Taiwan.

Who is sponsoring the NCT06230614 clinical trial?

NCT06230614 is sponsored by Fu Jen Catholic University. The principal investigator is Ke-Yun Chao, PhD at Fu Jen Catholic University Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology